NFKB1 and neoplasm: Sergej Skvortsov et al. found that CTFB, a novel anticancer drug, its anti-tumor activity was associated with down-regulation of NF-κB p65 expression by activation of proteasome in SCC-25 and CAL-27 cells [45].